Business Wire

InScope-AML and Regula Partner to Bolster Anti-Money Laundering Compliance Across Europe and Beyond

5.9.2023 10:00:00 EEST | Business Wire | Press release

Share

According to Regula’s survey*, 65% of organizations worldwide use digital document verification as one of their main methods of identity checks. And 94% of those who haven’t yet, plan to employ digital document verification in the next year. Responding to this growing demand for reliable and frictionless online ID verification, Regula and InScope-AML are joining forces to offer businesses across Europe and Africa a comprehensive and trustworthy solution for KYC and AML compliance management.

Being the first step of nearly all KYC procedures, identity document verification is of paramount importance and thus requires robust technology. After market research, InScope-AML chose to incorporate Regula Document Reader SDK into its existing solution. This move allows the company to enhance their proposition and uplevel document identification and verification among all their customers.

As an integral part of the InScope-AML solution, Regula Document Reader SDK automatically reads and authenticates IDs regardless of their type or issuing country. This is possible thanks to Regula’s proprietary database of document templates, which is the largest in the world and contains over 13,000 templates from 247 countries and territories. Apart from reading and validating data, Regula’s solution also cross-checks information from various data fields in the document to spot any possible inconsistencies that may indicate fraud.

The technology partnership between Regula and InScope-AML has made AML and KYC compliance even simpler and more effective while providing a seamless experience to customers. Not only does the InScope-AML solution protect businesses from serious consequences, such as reputational and financial risks, but it also helps them manage clients’ data intelligently. This possibility is enabled by Regula’s technology which analyzes document data and alerts users if some pieces of information need special attention, like an expiry date that is nearly overdue or when there is a mismatch between data provided by the client and the data on a document.

By incorporating Regula Document Reader SDK, the InScope-AML solution reinforces its overall security. The integration ensures that all personal data remains within the InScope-AML environment, granting full control over sensitive information to end users. This capability empowers users to deploy the solution on-premises, further enhancing data privacy and security measures.

Asked to comment about this partnership, Matt Rizzo, InScope-AML Chief Executive Officer, said, “Over the past years, InScope-AML has built a strong reputation around simplifying AML compliance and helping companies in 8 countries automate their AML processes to stay on track with compliance. Our partnership with Regula will now add a more comprehensive level of verification and substantially improve the quality of the data.”

“Today, compliance is a new reality for nearly all businesses. To succeed in this duty, it’s crucial to find a trustworthy solution that gives technology and resources to organize the process properly and at the same time provides a frictionless and enjoyable user experience. We are happy to partner with InScope-AML and to be a part of this transformation where compliance stops being a burden and becomes yet another intelligent layer of protection against fraud,” says Ihar Kliashchou, Chief Technology Officer at Regula.

* The research was initiated by Regula and conducted by Sapio Research in December 2022 and January 2023 using an online survey of 1,069 Fraud Detection/Prevention decision makers across the Financial Services (including Banking and FinTech), Technology, Telecoms, and Aviation sectors. The respondent geography included Australia, France, Germany, Mexico, Turkey, the UAE, the UK, and the USA.

About InScope-AML

At InScope-AML we have made it our mission to make AML compliance and KYC onboarding simple and effective, while providing a seamless experience to your customers.

Backed by the combined power of Cleverbit Software and Agilis IT Business Solutions, with a team of over 60 developers, as well as our experts in anti-money laundering regulation, we have created a solution which can be adapted to the needs of any operation, at a price which businesses of any size can afford.

Learn more at inscope-aml.com.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Proofing and Affirmation in 2022.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristina
ks@regulaforensics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye